Teva: The Pivot to Growth delivers 11th consecutive quarter of growth ($TEVA)

Shift to becoming a Biopharma company is working

Strategy

Teva’s “Pivot to Growth” continues to show results. What began as a defensive restructuring has become a deliberate transformation into an innovation-led biopharma with a credible growth engine. The company now combines a stabilized generics powerhouse with a rapidly expanding portfolio of neuroscience and immunology assets, while maintaining ri…